Legend Biotech (LEGN) Operating Income (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Operating Income data on file, last reported at -$19.7 million in Q4 2025.

• In Q4 2025, Operating Income rose 75.16% year-over-year to -$19.7 million; the TTM figure through Dec 2025 stood at $562.2 million (up 57.29% YoY), while the FY2025 annual figure was -$136.5 million, up 55.9% from the prior year.
• Operating Income grew to -$19.7 million in Q4 2025, from -$43.5 million in the prior quarter.
• Across five years, Operating Income topped out at $79.5 billion in Q4 2023 and bottomed at -$13.4 billion in Q1 2021.
• A 5-year average of $3.4 billion and a median of $116.1 million in 2022 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2021 — Operating Income sank 23850.29% — and 2023, when it jumped 72638.02%.
• Year by year, Operating Income stood at $89.8 million in 2021, then advanced by 21.62% to $109.2 million in 2022, then jumped by 72638.02% to $79.5 billion in 2023, then sank by 100.1% to -$79.3 million in 2024, then jumped by 75.16% to -$19.7 million in 2025.
• The last three Operating Income figures came in at -$19.7 million (Q4 2025), -$43.5 million (Q3 2025), and $337.9 million (Q2 2025), per Business Quant data.

Peer Comparison